Page 5 - காடீயேக் அறிவியல் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

How One Woman Turned a $40 Million Kuaishou Bet Into $12 Billion

How One Woman Turned a $40 Million Kuaishou Bet Into $12 Billion Bloomberg 2/9/2021 Zheping Huang, Coco Liu and Peter Elstrom (Bloomberg) In 2014, as their video app Kuaishou began to take off, Su Hua and his co-founders started looking for money to expand. They quickly got a proposal from Ruby Lu, a venture investor who had spotted them earlier as promising engineers and given them feedback on previous businesses. But Lu’s proposal was trumped by a larger venture firm with a much higher offer, according to people familiar with the matter. She refused to concede. Lu pitched Su and his team that she would give them more than money, offering her personal engagement and the support of her partners at DCM Ventures. She won, even with a lower offer.

United statesHong kongPalo altoBaltimore countyStanford universityJohns hopkins universityUniversity of marylandMenlo parkPortola valleyKai fu leeRandy pauschSu huaLei junStanley liTammy pauschKuaishou su

Secretive dealmaker lands US$14 bil hit with Kuaishou IPO

Last Friday, Kuaishou Technology started trading in Hong Kong after the biggest initial share sale for an internet company since Uber Technologies Inc in 2019.

United statesHong kongPalo altoBaltimore countyStanford universityJohns hopkins universityUniversity of marylandMenlo parkPortola valleyKai fu leeRandy pauschSu huaLei junStanley liTammy pauschKuaishou su

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Abeona Therapeutics Inc (NASDAQ:ABEO) - The Week Ahead In Biotech (Feb 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Abeona Therapeutics Inc (NASDAQ:ABEO) - The Week Ahead In Biotech (Feb 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United statesPacific biosciencesClovis oncology incSurmodics incJazz pharmaceuticalsCalifornia incInternational blood marrow transplant researchMerck co incExelixis incEquillium incBioventus incAvrobio incIncyte corporationProtalix biotherapeutics incDenali therapeutics incRegeneron pharmaceuticals inc

The Week Ahead In Biotech (Feb 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight

The Week Ahead In Biotech (Feb 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021

Share this article Share this article PALO ALTO, Calif., Feb. 2, 2021 /PRNewswire/ Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that a presentation of clinical study data on its investigational therapy KSI-301 will be made at the upcoming Angiogenesis, Exudation, and Degeneration 2021 – Virtual Edition meeting. Details of the presentation are as follows: Title: KSI-301: Intravitreal Antibody Biopolymer Conjugate that Demonstrates Extended Durability in Wet AMD and Retinal Vascular Diseases Presenter: Diana V. Do, M.D., Professor of Ophthalmology at Byers Eye Institute, Stanford University School of Medicine, Stanford, CA

Victor perlrothCompany phaseKodiak sciencesStanford university school of medicineProfessor of ophthalmology at byers eye instituteKodiak sciences incVirtual editionIntravitreal antibody biopolymer conjugateDemonstrates extended durabilityRetinal vascular diseasesByers eye instituteStanford university schoolChief executive officerAntibody biopolymer conjugatePalo altoவெற்றியாளர் பேர்ல்ரோத்